Enlarged Prostate Treatment: A Complete Guide to Medication, UroLift, Rezūm, TURP, Aquablation, HoLEP and PAE

An enlarged prostate is one of the most common reasons men consult a urologist—and one of the most treatable.

Nevertheless, many men live with a weak urinary stream, urgency, disturbed sleep or difficulty emptying their bladder for years before seeking help. Some assume that urinary problems are simply an unavoidable part of getting older. Others worry that the only effective treatment is major surgery carrying a high risk of incontinence, erectile dysfunction or loss of sexual function.

Neither assumption is correct.

The treatment of benign prostate enlargement has changed considerably. Alongside established medicines and traditional prostate surgery, there is now a range of minimally invasive and advanced surgical procedures. Some prioritise rapid recovery and preservation of ejaculation; others provide greater improvement in urinary flow and the lowest likelihood of needing further treatment.

The challenge is no longer simply deciding whether something can be done. It is choosing the treatment that best matches:

• the size and shape of the prostate;
• the underlying cause of the symptoms;
• bladder function;
• general health;
• the importance of preserving ejaculation;
• and the individual patient’s priorities.

This guide explains how an enlarged prostate causes urinary symptoms, how it should be assessed and what the principal treatment options involve—including the trade-offs that are sometimes difficult to cover during a short consultation.

In brief

An enlarged prostate does not always require treatment. Mild symptoms can often be managed with lifestyle changes or medication.

When an intervention is needed:

• UroLift and Rezūm prioritise preservation of ejaculation and relatively rapid recovery, but generally produce a smaller improvement than tissue-removing surgery and carry a greater possibility of further treatment.
• TURP remains a well-established and highly effective operation for moderately enlarged prostates.
• Aquablation combines robotic image guidance with tissue removal and may preserve ejaculation more often than TURP.
• HoLEP and other enucleation procedures provide highly durable treatment across a wide range of prostate sizes.
• Prostatic artery embolisation avoids an operation through the urethra but usually produces less improvement than conventional surgery and has a greater likelihood of retreatment.
• Simple prostatectomy is now mainly reserved for particularly large prostates when less invasive alternatives are unsuitable or unavailable.

No single treatment is best for every man.

---

What is an enlarged prostate?

The prostate is a gland situated immediately beneath the bladder. The urethra—the tube carrying urine from the bladder through the penis—passes directly through its centre.

In a younger man, the prostate is commonly around 20–25 ml in volume. As men age, cells in the inner part of the prostate may gradually increase in number, causing the gland to enlarge.

Several related terms are used:

• Benign prostatic hyperplasia, or BPH, describes the increase in prostate cells seen under a microscope.
• Benign prostatic enlargement, or BPE, means that the prostate has become measurably larger.
• Benign prostatic obstruction, or BPO, means that the enlargement is interfering with urine leaving the bladder.

These distinctions matter because a man may have a large prostate without significant obstruction, while another man with a relatively modestly enlarged prostate may have severe symptoms.

An enlarged prostate is not prostate cancer and does not turn into prostate cancer. The two conditions arise through different biological processes, although they become more common in the same age group and can coexist. Urinary symptoms therefore still require an appropriate assessment, including consideration of prostate-cancer risk where relevant.

---

What symptoms can an enlarged prostate cause?

Symptoms affecting the bladder and urinary stream are collectively called lower urinary tract symptoms, usually shortened to LUTS.

They are generally divided into three groups.

Voiding symptoms

These occur while passing urine and may include:

• a weak or slow stream;
• hesitancy before the flow begins;
• a stream that stops and starts;
• straining to pass urine;
• taking longer to empty the bladder;
• terminal dribbling;
• and a feeling that the bladder has not emptied completely.

Storage symptoms

These occur while the bladder is filling and include:

• passing urine more frequently;
• urinary urgency;
• waking at night to pass urine;
• difficulty postponing urination;
• and urgency incontinence.

Storage symptoms may develop because the bladder has been working against prostate obstruction, but they may also result from a separate bladder or medical problem. An overactive bladder, diabetes, neurological disease, sleep disturbance, medication and increased overnight urine production can all produce similar symptoms.

Post-micturition symptoms

These occur after urination and include:

• post-micturition dribbling;
• and the sensation that some urine remains trapped.

For many men, storage symptoms are more disruptive than a weak stream. Nocturia—waking repeatedly at night to pass urine—can fragment sleep, cause daytime fatigue and significantly affect quality of life.

---

Measuring symptom severity: the IPSS questionnaire

The International Prostate Symptom Score, or IPSS, is a seven-question questionnaire that measures urinary symptoms. Each answer is scored from 0 to 5, for a maximum total of 35.

An additional question asks how the symptoms affect quality of life.

The usual classifications are:

• 0–7: mild symptoms;
• 8–19: moderate symptoms;
• 20–35: severe symptoms.

The number is helpful, but it does not determine treatment by itself.

A man with a score of 18 who is not particularly troubled may reasonably choose observation. Another man with a score of 10 whose sleep, work or travel is being seriously affected may reasonably seek active treatment.

The most important question is often not simply, “How severe are the symptoms?” but:

How much are these symptoms affecting your life?

NICE recommends using a validated symptom score before treatment so that subsequent improvement can be measured objectively.

---

Why prostate size and symptom severity do not always match

There is only a loose relationship between prostate volume and urinary symptoms.

A 40 ml prostate with a prominent median lobe protruding into the bladder may produce severe obstruction. A 120 ml prostate that has expanded mainly outwards may cause surprisingly few symptoms.

The bladder itself is also important.

After years of working against resistance, the bladder muscle may become overactive, causing urgency and frequency. In other men, the bladder muscle gradually becomes weak and struggles to generate enough pressure to empty properly.

This means that apparently “prostate-related” symptoms may result from:

• prostate obstruction;
• an overactive bladder;
• an underactive bladder;
• excessive overnight urine production;
• urethral narrowing;
• infection;
• neurological disease;
• or a combination of several factors.

Operating on the prostate will not necessarily resolve symptoms caused mainly by the bladder or by a medical condition elsewhere in the body. A careful assessment is therefore essential before choosing treatment.

---

When should urinary symptoms be assessed urgently?

Most symptoms develop gradually and can be investigated through a routine GP or urology appointment.

Some situations require more urgent attention.

Seek urgent or same-day medical help if you have:

• complete inability to pass urine, particularly with a painful or swollen lower abdomen;
• visible blood in the urine accompanied by clots, heavy bleeding or difficulty urinating;
• fever, rigors, severe pain on urination or feeling systemically unwell;
• severe loin pain with urinary symptoms;
• or rapidly worsening symptoms accompanied by confusion or weakness.

Complete inability to urinate is called acute urinary retention. It normally requires emergency drainage of the bladder with a catheter.

Arrange prompt medical assessment if you have:

• any unexplained visible blood in the urine;
• recurrent urinary infections;
• persistent bladder pain;
• worsening urinary incontinence;
• unexplained weight loss;
• persistent bone pain;
• or a raised or rising PSA.

Chronic urinary retention may develop slowly and can be painless. The bladder can become markedly stretched, sometimes causing overflow leakage at night and, in severe cases, damage to kidney function.

---

How is an enlarged prostate assessed?

Assessment is not merely a formality. It identifies the likely cause of the symptoms, excludes more serious conditions and helps determine which treatments are suitable.

Medical history

The consultation should cover:

• the nature and duration of the symptoms;
• which symptoms are most troublesome;
• previous urinary infections or retention;
• visible blood in the urine;
• sexual and ejaculatory function;
• neurological and medical conditions;
• fluid, caffeine and alcohol intake;
• and previous prostate investigations.

A complete medication review is important. Diuretics, decongestants, antihistamines and some antidepressants can affect urination.

Symptom questionnaire

The IPSS provides a baseline to compare treatment results against later.

Frequency–volume chart

A frequency–volume chart records the time and amount of every urination, usually over three days.

Although completing one can feel laborious, it provides valuable information. It can distinguish:

• genuinely reduced bladder capacity;
• high fluid intake;
• urinary frequency caused by urgency;
• and nocturnal polyuria, in which a disproportionate amount of urine is produced overnight.

Nocturnal polyuria may be associated with excessive evening fluid intake, sleep apnoea, diabetes, heart or kidney conditions, leg swelling, medication or changes in overnight hormone production. Treating the prostate alone will not usually correct it.

Examination

This may include:

• examination of the abdomen for a full bladder;
• examination of the external genitalia where appropriate;
• and a digital rectal examination to assess the prostate’s approximate size, consistency and shape.

Urine testing

A urine test can identify:

• infection;
• blood;
• glucose;
• protein;
• and other abnormalities.

Blood tests

Kidney function is checked when there is concern about retention, recurrent infection or upper urinary-tract obstruction.

A PSA test may also be discussed. PSA can rise because of benign enlargement, inflammation, infection or prostate cancer. The result must therefore be interpreted in context rather than treated as a cancer test with a simple positive or negative answer.

Urinary flow rate and residual urine

During specialist assessment, a man may be asked to pass urine into a flow meter. A bladder scan then measures how much urine remains.

These tests provide objective information about flow strength and the effectiveness of bladder emptying.

Prostate imaging

Ultrasound may be used to measure prostate volume and assess its shape. An existing MRI scan may provide similar anatomical information when one has already been performed as part of a PSA or prostate-cancer assessment.

Prostate volume and the presence of a median lobe can materially affect which procedures are suitable.

Flexible cystoscopy

Flexible cystoscopy is a short examination of the urethra, prostate channel and bladder using a fine flexible telescope.

It is not required for every man with uncomplicated urinary symptoms. It may be recommended when there is:

• blood in the urine;
• recurrent infection;
• pain;
• suspected urethral narrowing;
• concern about bladder disease;
• or a need to define the anatomy before a particular procedure.

Urodynamics

Urodynamic pressure-flow testing examines how the bladder stores and expels urine.

It may be particularly useful when:

• the diagnosis is uncertain;
• poor bladder contractility is suspected;
• there is neurological disease;
• symptoms and flow-test results do not agree;
• previous treatment has failed;
• or the likelihood of improvement after surgery is unclear.

It is not necessary before every prostate operation, but it can be valuable in selected patients. NICE and European guidance support a tailored rather than one-size-fits-all approach to investigation.

---

Treatment options for an enlarged prostate

Treatment can be divided into three stages:

1. conservative management;
2. medication;
3. procedures or surgery.

Intervention may be recommended earlier when there are complications such as recurrent retention, bladder stones, recurrent infection, persistent prostate bleeding or impaired kidney function caused by obstruction.

---

Stage one: lifestyle changes and conservative management

Men with mild or non-bothersome symptoms do not necessarily require medication or surgery. Symptoms do not inevitably progress, and some remain stable for many years.

Measures that may help include the following.

Adjust the timing of fluids

The aim is not necessarily to drink less overall. It is often more helpful to redistribute fluid intake and reduce drinking during the three or four hours before bed.

Men with heart or kidney conditions should follow individual medical advice rather than imposing a general fluid target.

Reduce caffeine and alcohol

Caffeine can increase urine production and bladder urgency. Alcohol may have both a diuretic effect and an adverse effect on bladder control.

Reducing either can improve frequency, urgency and nocturia.

Use double voiding

After passing urine, wait briefly, relax and try again. This may help some men empty more completely.

Try urethral milking

For post-micturition dribbling, gently press behind the scrotum and move forward after urination to help clear urine remaining in the urethra.

Treat constipation

A full rectum can worsen urinary symptoms and make bladder emptying more difficult.

Consider bladder training

Supervised bladder training can help men whose symptoms are dominated by urgency and frequency. It involves gradually increasing the interval between trips to the toilet rather than urinating repeatedly “just in case”.

Review medication

Changing the timing of a diuretic or reviewing a medicine that affects bladder function can sometimes produce a meaningful improvement.

Do not stop medication without first discussing it with the prescribing clinician.

Maintain a healthy weight and remain active

Regular activity, weight management and good general cardiovascular health may reduce symptom burden and benefit erectile and bladder function.

Conservative management should include review if symptoms change or become more troublesome.

---

Stage two: medication

Medication is generally considered when symptoms are bothersome, and lifestyle changes have not provided enough relief.

The choice depends on whether the main problem is obstruction, prostate growth, bladder overactivity, nocturnal urine production or a combination of these.

Alpha-blockers

Examples include:

• tamsulosin;
• alfuzosin;
• doxazosin;
• and silodosin.

Alpha-blockers relax smooth muscle around the prostate and bladder neck. They do not shrink the prostate, but they reduce resistance around the urethra.

Benefits may begin within days and are generally apparent within several weeks.

Possible side effects include:

• dizziness;
• postural light-headedness;
• tiredness;
• nasal congestion;
• and reduced or absent forward ejaculation.

Ejaculatory disturbance is particularly associated with highly selective drugs such as tamsulosin and silodosin and usually resolves when the medication is stopped.

Men who have taken an alpha-blocker should tell their ophthalmologist before cataract surgery because of the risk of intraoperative floppy iris syndrome.

5-alpha reductase inhibitors

The principal drugs are:

• finasteride;
• and dutasteride.

These reduce conversion of testosterone to dihydrotestosterone, gradually shrinking prostate tissue.

They are most useful in men with a genuinely enlarged prostate and an increased risk of future progression. Their effect develops slowly, usually over several months.

Unlike alpha-blockers, they can reduce the longer-term likelihood of:

• acute urinary retention;
• progression of prostate enlargement;
• and eventual prostate surgery.

Possible side effects include:

• reduced libido;
• erectile dysfunction;
• reduced ejaculate volume;
• breast tenderness or enlargement;
• and ejaculatory difficulty.

These medicines commonly reduce PSA by approximately half after six months. PSA interpretation must therefore be adjusted, and a rising PSA while taking a 5-alpha reductase inhibitor should be investigated appropriately.

Combination therapy

Combining an alpha-blocker with a 5-alpha reductase inhibitor offers:

• faster relief from the alpha-blocker;
• and longer-term protection from the 5-alpha reductase inhibitor.

It is often considered for men with bothersome symptoms and a substantially enlarged prostate.

Once the slower-acting drug has taken effect, some men may be able to stop the alpha-blocker and continue the 5-alpha reductase inhibitor alone.

Medication for bladder-storage symptoms

When urgency, frequency and urgency incontinence dominate—and the bladder is emptying reasonably well—an additional bladder medicine may be considered.

Options include:

• an antimuscarinic such as solifenacin or tolterodine;
• mirabegron;
• or vibegron.

Antimuscarinics can cause dry mouth, constipation and, in susceptible men, increased difficulty emptying the bladder.

Beta-3 agonists such as mirabegron and vibegron relax the bladder through a different mechanism and may be useful when antimuscarinic side effects are unacceptable. Blood pressure and other contraindications should be considered.

Tadalafil

Tadalafil 5 mg once daily is licensed for male urinary symptoms and can be particularly attractive for men who also have erectile dysfunction.

It may improve symptom scores, although it does not shrink the prostate or clearly reduce the risk of retention or future surgery.

NHS availability for urinary symptoms alone varies. NICE CG97 currently advises against offering a PDE5 inhibitor solely for male LUTS outside a trial, whereas European guidance supports tadalafil in appropriately selected men. It must not be combined with nitrate medication and is unsuitable for some men with significant cardiovascular disease.

Desmopressin

Desmopressin may be considered when a bladder diary confirms nocturnal polyuria rather than obstruction as the main cause of nocturia.

It reduces urine production overnight, but it can lower blood sodium levels. Hyponatraemia can be serious and is more common in older patients.

Treatment requires careful patient selection and sodium testing before and after starting medication. Sleep apnoea, heart failure, leg oedema, diabetes and other medical causes of nocturia should be addressed first.

Herbal supplements

Saw palmetto and other prostate supplements are widely marketed, but products differ considerably in their extraction methods, composition and quality.

NICE does not recommend phytotherapy for male urinary symptoms. European guidance notes limited evidence of modest benefit from one particular hexane-extracted saw-palmetto preparation, but this should not be assumed to apply to all products.

Supplements should not delay proper assessment or established treatment.

---

Stage three: procedures and surgery

A procedure may be considered when:

• medication has not provided enough benefit;
• side effects are unacceptable;
• the patient does not want long-term medication;
• symptoms are significantly affecting quality of life;
• or complications of obstruction have developed.

The options fall into three broad families.

---

Family one: minimally invasive treatments that do not surgically remove a large volume of tissue

These procedures generally prioritise:

• preservation of ejaculation;
• shorter hospital stays;
• and faster initial recovery.

The trade-off is that flow improvement may be smaller, and the likelihood of further treatment may be higher than after definitive tissue-removing surgery.

UroLift: prostatic urethral lift

UroLift uses small permanent implants to draw the obstructing prostate lobes away from the urethra.

No prostate tissue is cut, heated or removed.

Potential advantages include:

• day-case or outpatient treatment;
• relatively rapid improvement;
• short recovery;
• little or no catheterisation in many patients;
• and a low risk of new erectile or ejaculatory dysfunction.

It is generally best suited to men with:

• moderately enlarged prostates;
• predominantly lateral-lobe obstruction;
• and no significantly obstructing median lobe.

NICE supports UroLift for patients aged 50 and over with prostates between 30 and 80 ml. European guidance is more restrictive and recommends it particularly for prostates below 70 ml without a middle lobe.

The improvement is usually less pronounced than after TURP or enucleation. Patients should also understand that repeat treatment is more common than after definitive tissue-removing surgery.

Rezūm water-vapour therapy

Rezūm uses controlled bursts of sterile water vapour to deliver thermal energy into obstructing prostate tissue.

The treated tissue gradually shrinks over the following weeks and months.

Potential advantages include:

• day-case treatment;
• suitability for some median lobes;
• low rates of erectile dysfunction;
• preservation of ejaculation in most men;
• and avoidance of major tissue resection.

Symptoms do not improve immediately. Temporary swelling may initially make urination worse, and a catheter may be required for several days or occasionally longer.

NICE supports Rezūm for moderate-to-severe symptoms in moderately enlarged prostates, typically between 30 and 80 ml.

Rezūm generally produces greater improvement than medication but less improvement in flow than TURP or enucleation. Its longer-term durability is encouraging, although some men will eventually need another procedure.

Temporary implantable nitinol device: iTIND

The iTIND is a temporary device placed within the prostate channel for several days and then removed.

It applies pressure at selected points, creating channels that reshape the bladder neck and prostatic urethra.

It may appeal to men seeking a tissue-preserving treatment with a low risk of sexual side effects. However, availability is limited, and its evidence base is less mature than that for TURP, UroLift or Rezūm.

It should be regarded as a newer option rather than an established equivalent to definitive surgery.

Prostatic artery embolisation

Prostatic artery embolisation, or PAE, is performed by an interventional radiologist.

An interventional radiologist introduces a fine catheter through an artery in the wrist or groin and guides it to the blood vessels supplying the prostate. Tiny particles are then injected to reduce the blood supply, causing the prostate to shrink gradually.

Potential advantages include:

• local rather than general anaesthesia;
• no surgical instrument passing through the prostate channel;
• treatment of some very large prostates;
• and an option for selected men with increased anaesthetic or surgical risk.

However:

• improvement in symptoms and urinary flow is usually less than after TURP or enucleation;
• results can be variable;
• repeat intervention is more common;
• and the procedure is technically demanding.

Patient selection should be undertaken jointly by a urologist and an interventional radiologist. NICE states that a radiologist with specific training and expertise should perform the procedure.

Blood-thinning medication still requires an individual management plan; PAE should not be assumed to carry no bleeding risk simply because it avoids transurethral surgery.

Optilume BPH

Optilume BPH uses a drug-coated balloon to dilate the prostate channel and deliver an antiproliferative medication to the treated tissue.

Early studies are promising, particularly regarding symptom improvement and preservation of sexual function. However, long-term comparative evidence remains less mature than for established surgical procedures, and availability in the UK is limited.

Patients considering it should be told clearly that it is a relatively new treatment with less long-term evidence.

---

Family two: procedures that incise, remove or destroy obstructing prostate tissue

These treatments generally produce a larger and more durable improvement in urinary flow.

The principal trade-offs are:

• a greater likelihood of retrograde ejaculation;
• a longer recovery than after some minimally invasive treatments;
• and the usual risks associated with anaesthesia and surgery.

Transurethral incision of the prostate

Transurethral incision of the prostate, or TUIP, is mainly used for men with small prostates—often below 30 ml—without a significant median lobe.

Instead of removing tissue, the surgeon makes one or two incisions through the bladder neck and prostate to release the constriction.

Compared with TURP, TUIP may offer:

• a shorter operation;
• less bleeding;
• and a lower likelihood of retrograde ejaculation.

Its main disadvantage is a greater possibility of needing another procedure in the future.

TURP: transurethral resection of the prostate

TURP has been the benchmark operation for benign prostate obstruction for many decades.

An electrical loop is passed through the urethra and used to remove the obstructing central prostate tissue in small pieces.

Modern bipolar TURP uses saline irrigation, substantially reducing the risk of the dilutional “TUR syndrome” associated with older monopolar systems.

TURP is particularly well established for prostates in the approximately 30–80 ml range.

Potential benefits include:

• substantial improvement in symptom scores;
• a stronger urinary stream;
• improved bladder emptying;
• and good long-term durability.

Important trade-offs include:

• retrograde ejaculation in a substantial majority of men;
• bleeding;
• infection;
• urethral stricture;
• bladder-neck contracture;
• and a small risk of urinary incontinence.

The removed tissue is sent for histological examination, which occasionally identifies unsuspected prostate cancer.

GreenLight laser vaporisation

GreenLight photoselective vaporisation uses laser energy to vaporise obstructing prostate tissue.

Because the laser also seals blood vessels, bleeding may be reduced compared with some other operations. This can be useful for selected patients with an increased bleeding risk, although anticoagulant and antiplatelet medication still requires individual planning.

Potential advantages include:

• good improvement in symptoms and flow;
• short catheterisation;
• and a relatively short hospital stay.

Because tissue is vaporised rather than collected, there is normally no specimen for histology.

Retrograde ejaculation remains common.

Aquablation

Aquablation is a robotically executed, image-guided treatment.

The surgeon uses real-time ultrasound to map the prostate and define which tissue should be removed. A robotically controlled, high-velocity saline jet then removes the planned tissue without using heat for the principal resection.

Potential advantages include:

• precise treatment planned around individual anatomy;
• short resection time;
• substantial improvement in symptoms and urinary flow;
• treatment across a broad range of prostate sizes;
• and better preservation of forward ejaculation than conventional TURP in comparative studies.

The strongest randomised evidence is in prostates between 30 and 80 ml, where Aquablation provides functional outcomes comparable with TURP.

Prospective studies also support its use in larger prostates (80-150 ml), although comparative evidence in this group is less mature than for standard-sized glands.

Five-year data show durable improvement and a low overall need for surgical retreatment. It would nevertheless be inaccurate to promise greater durability than TURP; both provide durable treatment, and precise retreatment findings vary by study and outcome measured.

Bleeding is the principal early consideration. Most men require a catheter for one or two days, although practice varies.

NICE supports transurethral water-jet ablation under standard arrangements for governance, consent, and audit.

HoLEP and other endoscopic enucleation procedures

HoLEP stands for holmium laser enucleation of the prostate.

Rather than shaving away prostate tissue piece by piece, the surgeon identifies the natural plane between the benign adenoma and the outer surgical capsule. The obstructing lobes are separated from the capsule, moved into the bladder and divided with a morcellator for removal.

Other enucleation techniques use different lasers or bipolar electrical energy but follow the same anatomical principle.

Potential advantages include:

• treatment across almost any prostate size;
• substantial improvement in urinary flow;
• removal of a large proportion of the obstructing tissue;
• tissue for histological examination;
• and excellent long-term durability.

Important considerations include:

• a significant surgical learning curve;
• temporary urinary leakage in some men during the early recovery period;
• retrograde ejaculation in the large majority;
• bleeding and infection;
• and a small risk of urethral or bladder-neck scarring.

Surgeon experience influences outcomes, particularly during the learning phase.

Simple prostatectomy

Simple prostatectomy removes the central benign adenoma while leaving the outer prostate capsule behind.

It differs from radical prostatectomy, which removes the whole prostate for cancer.

Simple prostatectomy may be performed:

• robotically;
• laparoscopically;
• or through an open incision.

It is now mainly reserved for very large prostates when endoscopic enucleation, Aquablation or another less invasive approach is unavailable or unsuitable.

Robotic and laparoscopic techniques have reduced blood loss and recovery time compared with traditional open surgery, but simple prostatectomy remains more invasive than transurethral treatment.

---

Family three: managing bladder emptying without correcting the prostate obstruction

Not every man is suitable for surgery, and not every man wishes to undergo it.

Alternative options include:

Intermittent self-catheterisation

A catheter is inserted periodically to empty the bladder and then removed.

Many men manage this independently and maintain a good quality of life. Where feasible, it is generally preferable to having a permanent urethral catheter in place.

Long-term urethral catheter

A catheter remains within the bladder and drains continuously into a bag or valve.

Suprapubic catheter

A catheter is inserted through the lower abdomen directly into the bladder.

Long-term catheterisation can be entirely appropriate for selected patients, but it carries risks including:

• infection;
• catheter blockage;
• bladder stones;
• bleeding;
• and urethral damage with a long-term urethral catheter.

These are legitimate management choices rather than treatment failures, but they should follow a genuine discussion of all realistic alternatives.

---

Comparing enlarged-prostate treatments

Treatment	Typical prostate anatomy	Anaesthetic	Catheter	Ejaculation	Relative durability
UroLift	Usually 30–80 ml; best established without obstructing median lobe	Local, sedation or general	Often none or brief	Usually preserved	Moderate
Rezūm	Usually 30–80 ml; median lobe may be treated	Local, sedation or general	Several days; sometimes longer	Usually preserved	Good
iTIND	Smaller selected prostates	Local, sedation or general	Variable	Usually preserved	Evidence still developing
PAE	Variable; often considered for larger glands or selected higher-risk patients	Local	Variable	Usually preserved	Variable; retreatment more common
TUIP	Usually below 30 ml without significant median lobe	General or spinal	Usually short	More often preserved than after TURP	Good, but repeat treatment more likely
TURP	Commonly 30–80 ml	General or spinal	Usually 1–2 days	Usually not preserved	Excellent
GreenLight PVP	Commonly moderate-sized prostates	General or spinal	Often around 1 day	Usually not preserved	Very good
Aquablation	Strongest comparative evidence at 30–80 ml; also used in larger glands	General or spinal	Usually 1–2 days	Preserved more often than after TURP	Good five-year durability
HoLEP or other enucleation	Almost any size	General or spinal	Usually 1–2 days	Usually not preserved	Excellent
Simple prostatectomy	Usually very large prostates	General	Several days	Usually not preserved	Excellent

These ranges are guides rather than absolute rules. Suitability depends on anatomy, bladder function, comorbidities, previous treatment, available expertise and the individual patient’s priorities.

---

How is the right treatment chosen?

A good consultation should consider more than prostate size alone.

1. Prostate volume and shape

A small obstructing prostate requires a different approach from a 150 ml gland.

The presence of a median lobe, calcification, a high bladder neck or unusual anatomy may rule particular procedures in or out.

2. Bladder function

Symptoms may arise from:

• obstruction;
• bladder overactivity;
• poor bladder contractility;
• or a combination.

Removing prostate tissue cannot guarantee normal urination if the bladder muscle itself has become weak.

3. The symptoms that matter most

One man may be most troubled by a weak stream. Another may be concerned almost entirely by urgency or nocturia.

The treatment should target the symptom-generating mechanism rather than simply the existence of an enlarged prostate.

4. The importance of ejaculation

This should be discussed directly.

For some men, preservation of ejaculation is one of the most important treatment goals. For others, it has little influence on the decision. Neither position is wrong.

The answer may materially change the choice between:

• a tissue-preserving procedure;
• Aquablation;
• TURP;
• or enucleation.

5. General health and blood-thinning medication

Cardiac, respiratory and neurological health may affect the safest anaesthetic and procedure.

The reason for anticoagulation, the medication used and the risk of temporarily interrupting it must all be considered individually.

6. Urinary retention

A man who has repeatedly gone into retention may benefit more from definitive tissue removal than from a procedure designed mainly to provide modest symptom relief.

The likelihood of catheter independence also depends on bladder contractility.

7. Willingness to accept repeat treatment

Some men prefer a minimally invasive procedure even after understanding that another treatment may eventually be necessary.

Others prioritise maximum durability and accept a more invasive operation or a higher likelihood of retrograde ejaculation.

8. Surgeon and hospital experience

Some procedures depend heavily on training and case volume.

It is reasonable to ask:

• how often the surgeon performs the procedure;
• what their usual outcomes are;
• how complications are recorded;
• and what alternatives they personally offer.

Don’t choose treatment simply because it is the only procedure available in a particular unit.

---

What is recovery really like?

Recovery differs substantially between procedures.

After UroLift

Men may experience:

• burning on urination;
• urgency;
• pelvic discomfort;
• light bleeding;
• and increased frequency.

These symptoms generally improve over days or a few weeks.

After Rezūm

Temporary swelling can initially worsen obstruction.

Men may experience:

• urinary discomfort;
• urgency and frequency;
• blood in the urine or semen;
• and a need for catheterisation.

Improvement develops gradually over several weeks and may continue for several months.

After TURP, Aquablation, laser treatment or enucleation

Common experiences include:

• burning while passing urine;
• urgency and frequency;
• intermittent blood in the urine;
• tiredness;
• and temporary fluctuations in urinary control.

Bleeding may briefly recur as the internal healing surface separates.

After enucleation, some men experience temporary stress leakage, particularly when coughing or exercising. This usually improves as healing progresses and pelvic-floor control recovers.

Activity after surgery

Advice varies according to the operation and the individual patient, but commonly includes:

• avoiding heavy lifting and strenuous exercise initially;
• preventing constipation and straining;
• drinking enough fluid unless medically restricted;
• avoiding long journeys during the early recovery period;
• and following specific advice about driving, work and sexual activity.

Some men return to office work within one or two weeks after a transurethral operation. Others need longer, particularly after a more extensive procedure or physically demanding work.

Judge final symptom results over months rather than days.

Seek urgent advice after a procedure if you:

• cannot pass urine;
• develop a fever or rigors;
• feel systemically unwell;
• experience heavy bleeding;
• pass persistent clots;
• develop severe pain;
• or have a catheter that stops draining.

---

Risks to understand before giving consent

The risk profile varies between treatments, but you should normally discuss the following issues.

Retrograde ejaculation

Semen passes backwards into the bladder rather than forwards through the penis.

It does not usually remove the sensation of orgasm, but it changes the experience of climax and affects natural fertility.

It is common after TURP, GreenLight vaporisation and enucleation, and less common after UroLift, Rezūm and Aquablation.

Erectile dysfunction

New erectile dysfunction is uncommon after modern benign-prostate surgery, although individual risk depends on age, vascular health, pre-existing erectile function and the procedure performed.

Bleeding

Bleeding may occasionally require:

• prolonged catheterisation;
• bladder washout;
• readmission;
• a return to theatre;
• or, rarely, blood transfusion.

Infection

Urinary infection can occur after any intervention. Rarely, infection may involve the testicle or epididymis.

Urethral stricture or bladder-neck contracture

Scar tissue can narrow the urethra or bladder outlet months or years after surgery, causing recurrent poor flow.

Urinary incontinence

Permanent stress incontinence is uncommon after surgery for benign enlargement, but temporary leakage may occur, particularly after enucleation.

Failure to improve

Surgery may not completely resolve symptoms if:

• the bladder is overactive;
• the bladder muscle is weak;
• nocturnal polyuria is present;
• or more than one condition is causing the symptoms.

Further treatment

Every treatment has a possibility of retreatment, but the likelihood varies considerably.

In general, minimally invasive tissue-preserving treatments trade some durability for faster recovery and better preservation of ejaculation.

---

Frequently asked questions

---

When should you see a urologist?

Consider specialist assessment if you have:

• moderate or severe symptoms affecting quality of life;
• symptoms that have not improved with initial medication;
• recurrent urinary infection;
• visible blood in the urine;
• a raised or rising PSA;
• difficulty emptying the bladder;
• a significant residual urine volume;
• bladder stones;
• kidney impairment;
• or any episode of urinary retention.

Useful information to bring to the appointment includes:

• a completed IPSS questionnaire;
• a three-day frequency–volume chart;
• an up-to-date medication list;
• previous PSA results;
• relevant scan or biopsy results;
• and a clear sense of which symptoms trouble you most.

It is also worth considering what you are—and are not—prepared to trade for improvement.

For example:

• Is preserving ejaculation a priority?
• Would you accept a greater likelihood of repeat treatment in exchange for a less invasive procedure?
• Do you want to avoid long-term medication?
• Is maximum improvement in flow more important than speed of recovery?

The right treatment is not simply the newest treatment or the most extensive operation. It is the option that provides the most appropriate balance of symptom improvement, durability, recovery and side effects for the individual patient.

---

Arrange an enlarged-prostate assessment

If you have a weak urinary stream, urgency, nocturia, incomplete bladder emptying or an enlarged-prostate diagnosis, I can assess the cause of your symptoms and explain which treatment options are appropriate for you.

You can learn more about my enlarged-prostate assessment and treatment service or arrange an appointment through my private urology contact page

.

Consultations are available at several clinic locations across Buckinghamshire, Berkshire, Oxfordshire and London. Information for self-pay and insured patients is available on my fees and private medical insurance page.

References and further guidance

• National Institute for Health and Care Excellence. Lower urinary tract symptoms in men: management. NICE guideline CG97. Published 2010; updated 2015; reviewed December 2024.
• National Institute for Health and Care Excellence. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. HealthTech guidance HTG578.
• National Institute for Health and Care Excellence. Rezūm for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. HealthTech guidance HTG545.
• National Institute for Health and Care Excellence. Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. HealthTech guidance HTG691.
• National Institute for Health and Care Excellence. Prostatic artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. HealthTech guidance HTG469.
• European Association of Urology. Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. 2026 edition.

---

This article provides general information and does not replace an individual medical consultation. Urinary symptoms can have several causes, and the most appropriate treatment depends on a full assessment of the prostate, bladder, general health and personal priorities.

Author: Mr Neil Haldar, Consultant Urological Surgeon
GMC number: 3683914